In the past week, RSLS stock has gone down by -36.57%, with a monthly decline of -22.15% and a quarterly plunge of -90.59%. The volatility ratio for the week is 17.12%, and the volatility levels for the last 30 days are 16.52% for ReShape Lifesciences Inc The simple moving average for the past 20 days is -28.44% for RSLS’s stock, with a -94.36% simple moving average for the past 200 days.
Is It Worth Investing in ReShape Lifesciences Inc (NASDAQ: RSLS) Right Now?
The 36-month beta value for RSLS is at 1.44. Analysts have varying views on the stock, with 0 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for RSLS is 0.72M, and currently, shorts hold a 10.13% of that float. The average trading volume for RSLS on May 12, 2025 was 721.50K shares.
RSLS) stock’s latest price update
ReShape Lifesciences Inc (NASDAQ: RSLS)’s stock price has dropped by -20.07 in relation to previous closing price of 8.33. Nevertheless, the company has seen a loss of -36.57% in its stock price over the last five trading days. globenewswire.com reported 2025-05-07 that IRVINE, Calif., May 07, 2025 (GLOBE NEWSWIRE) — ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that its Board of Directors has declared a 1-for-25 reverse stock split of the company’s common stock, which will be effective for trading purposes upon the commencement of trading on May 9, 2025.
RSLS Trading at -51.53% from the 50-Day Moving Average
After a stumble in the market that brought RSLS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -99.08% of loss for the given period.
Volatility was left at 16.52%, however, over the last 30 days, the volatility rate increased by 17.12%, as shares sank -52.98% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -75.78% lower at present.
During the last 5 trading sessions, RSLS fell by -36.57%, which changed the moving average for the period of 200-days by -97.84% in comparison to the 20-day moving average, which settled at $9.31. In addition, ReShape Lifesciences Inc saw -94.03% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at RSLS starting from STANKOVICH THOMAS, who sale 48 shares at the price of $0.25 back on May 31 ’24. After this action, STANKOVICH THOMAS now owns 22,777 shares of ReShape Lifesciences Inc, valued at $12 using the latest closing price.
Stock Fundamentals for RSLS
Current profitability levels for the company are sitting at:
- -0.83 for the present operating margin
- 0.63 for the gross margin
The net margin for ReShape Lifesciences Inc stands at -0.89. The total capital return value is set at 34.73. Equity return is now at value -222.50, with -92.30 for asset returns.
Based on ReShape Lifesciences Inc (RSLS), the company’s capital structure generated 1.35 points at debt to capital in total, while cash flow to debt ratio is standing at -4.58.
Currently, EBITDA for the company is -6.67 million with net debt to EBITDA at -0.04. When we switch over and look at the enterprise to sales, we see a ratio of 9.41. The receivables turnover for the company is 8.11for trailing twelve months and the total asset turnover is 1.67. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.90.
Conclusion
In conclusion, ReShape Lifesciences Inc (RSLS) has had a bad performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
